Algorithmic approach for methyl-CpG binding protein 2 (MECP2) gene testing in patients with neurodevelopmental disabilities

Jennifer N Sanmann, G. Bradley Schaefer, Bruce A. Buehler, Warren G. Sanger

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Methyl-CpG binding protein 2 gene (MECP2) testing is indicated for patients with numerous clinical presentations, including Rett syndrome (classic and atypical), unexplained neonatal encephalopathy, Angelman syndrome, nonspecific mental retardation, autism (females), and an X-linked family history of developmental delay. Because of this complexity, a gender-specific approach for comprehensive MECP2 gene testing is described. Briefly, sequencing of exons 1 to 4 of MECP2 is recommended for patients with a Rett syndrome phenotype, unexplained neonatal encephalopathy, an Angelman syndrome phenotype (with negative 15q11-13 analysis), nonspecific mental retardation, or autism (females). Additional testing for large-scale MECP2 deletions is recommended for patients with Rett syndrome or Angelman syndrome phenotypes (with negative 15q11-13 analysis) following negative sequencing. Alternatively, testing for large-scale MECP2 duplications is recommended for males presenting with mental retardation, an X-linked family history of developmental delay, and a significant proportion of previously described clinical features (particularly a history of recurrent respiratory infections).

Original languageEnglish (US)
Pages (from-to)346-354
Number of pages9
JournalJournal of Child Neurology
Volume27
Issue number3
DOIs
StatePublished - Mar 1 2012

Fingerprint

Methyl-CpG-Binding Protein 2
Angelman Syndrome
Rett Syndrome
Genes
Brain Diseases
Autistic Disorder
Phenotype
Intellectual Disability
X-Linked Mental Retardation
Respiratory Tract Infections
Exons

Keywords

  • Angelman syndrome
  • Rett syndrome
  • deletion/duplication
  • methyl-CpG binding protein 2 (MECP2)
  • neonatal encephalopathy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Algorithmic approach for methyl-CpG binding protein 2 (MECP2) gene testing in patients with neurodevelopmental disabilities. / Sanmann, Jennifer N; Schaefer, G. Bradley; Buehler, Bruce A.; Sanger, Warren G.

In: Journal of Child Neurology, Vol. 27, No. 3, 01.03.2012, p. 346-354.

Research output: Contribution to journalReview article

@article{3de4d03450c442a1a84ac9f0909a2b6f,
title = "Algorithmic approach for methyl-CpG binding protein 2 (MECP2) gene testing in patients with neurodevelopmental disabilities",
abstract = "Methyl-CpG binding protein 2 gene (MECP2) testing is indicated for patients with numerous clinical presentations, including Rett syndrome (classic and atypical), unexplained neonatal encephalopathy, Angelman syndrome, nonspecific mental retardation, autism (females), and an X-linked family history of developmental delay. Because of this complexity, a gender-specific approach for comprehensive MECP2 gene testing is described. Briefly, sequencing of exons 1 to 4 of MECP2 is recommended for patients with a Rett syndrome phenotype, unexplained neonatal encephalopathy, an Angelman syndrome phenotype (with negative 15q11-13 analysis), nonspecific mental retardation, or autism (females). Additional testing for large-scale MECP2 deletions is recommended for patients with Rett syndrome or Angelman syndrome phenotypes (with negative 15q11-13 analysis) following negative sequencing. Alternatively, testing for large-scale MECP2 duplications is recommended for males presenting with mental retardation, an X-linked family history of developmental delay, and a significant proportion of previously described clinical features (particularly a history of recurrent respiratory infections).",
keywords = "Angelman syndrome, Rett syndrome, deletion/duplication, methyl-CpG binding protein 2 (MECP2), neonatal encephalopathy",
author = "Sanmann, {Jennifer N} and Schaefer, {G. Bradley} and Buehler, {Bruce A.} and Sanger, {Warren G.}",
year = "2012",
month = "3",
day = "1",
doi = "10.1177/0883073811424796",
language = "English (US)",
volume = "27",
pages = "346--354",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Algorithmic approach for methyl-CpG binding protein 2 (MECP2) gene testing in patients with neurodevelopmental disabilities

AU - Sanmann, Jennifer N

AU - Schaefer, G. Bradley

AU - Buehler, Bruce A.

AU - Sanger, Warren G.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Methyl-CpG binding protein 2 gene (MECP2) testing is indicated for patients with numerous clinical presentations, including Rett syndrome (classic and atypical), unexplained neonatal encephalopathy, Angelman syndrome, nonspecific mental retardation, autism (females), and an X-linked family history of developmental delay. Because of this complexity, a gender-specific approach for comprehensive MECP2 gene testing is described. Briefly, sequencing of exons 1 to 4 of MECP2 is recommended for patients with a Rett syndrome phenotype, unexplained neonatal encephalopathy, an Angelman syndrome phenotype (with negative 15q11-13 analysis), nonspecific mental retardation, or autism (females). Additional testing for large-scale MECP2 deletions is recommended for patients with Rett syndrome or Angelman syndrome phenotypes (with negative 15q11-13 analysis) following negative sequencing. Alternatively, testing for large-scale MECP2 duplications is recommended for males presenting with mental retardation, an X-linked family history of developmental delay, and a significant proportion of previously described clinical features (particularly a history of recurrent respiratory infections).

AB - Methyl-CpG binding protein 2 gene (MECP2) testing is indicated for patients with numerous clinical presentations, including Rett syndrome (classic and atypical), unexplained neonatal encephalopathy, Angelman syndrome, nonspecific mental retardation, autism (females), and an X-linked family history of developmental delay. Because of this complexity, a gender-specific approach for comprehensive MECP2 gene testing is described. Briefly, sequencing of exons 1 to 4 of MECP2 is recommended for patients with a Rett syndrome phenotype, unexplained neonatal encephalopathy, an Angelman syndrome phenotype (with negative 15q11-13 analysis), nonspecific mental retardation, or autism (females). Additional testing for large-scale MECP2 deletions is recommended for patients with Rett syndrome or Angelman syndrome phenotypes (with negative 15q11-13 analysis) following negative sequencing. Alternatively, testing for large-scale MECP2 duplications is recommended for males presenting with mental retardation, an X-linked family history of developmental delay, and a significant proportion of previously described clinical features (particularly a history of recurrent respiratory infections).

KW - Angelman syndrome

KW - Rett syndrome

KW - deletion/duplication

KW - methyl-CpG binding protein 2 (MECP2)

KW - neonatal encephalopathy

UR - http://www.scopus.com/inward/record.url?scp=84858658888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858658888&partnerID=8YFLogxK

U2 - 10.1177/0883073811424796

DO - 10.1177/0883073811424796

M3 - Review article

C2 - 22123427

AN - SCOPUS:84858658888

VL - 27

SP - 346

EP - 354

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 3

ER -